JP2018512403A - 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 - Google Patents

置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 Download PDF

Info

Publication number
JP2018512403A
JP2018512403A JP2017548211A JP2017548211A JP2018512403A JP 2018512403 A JP2018512403 A JP 2018512403A JP 2017548211 A JP2017548211 A JP 2017548211A JP 2017548211 A JP2017548211 A JP 2017548211A JP 2018512403 A JP2018512403 A JP 2018512403A
Authority
JP
Japan
Prior art keywords
dihydroimidazo
methoxy
quinazolin
morpholin
ylpropoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017548211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512403A5 (enExample
Inventor
リウ，ニーンシュウ
ピーナ，キャロル
ジェファーズ，マイケル
ジャンブレス，イザベル
Original Assignee
バイエル ファーマ アクチエンゲゼルシャフト
バイエル ファーマ アクチエンゲゼルシャフト
バイエル・ヘルスケア・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイエル ファーマ アクチエンゲゼルシャフト, バイエル ファーマ アクチエンゲゼルシャフト, バイエル・ヘルスケア・ファーマシューティカルズ・インコーポレイテッド filed Critical バイエル ファーマ アクチエンゲゼルシャフト
Publication of JP2018512403A publication Critical patent/JP2018512403A/ja
Publication of JP2018512403A5 publication Critical patent/JP2018512403A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2017548211A 2015-03-09 2016-03-07 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 Withdrawn JP2018512403A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130547P 2015-03-09 2015-03-09
US62/130,547 2015-03-09
PCT/EP2016/054728 WO2016142313A1 (en) 2015-03-09 2016-03-07 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Publications (2)

Publication Number Publication Date
JP2018512403A true JP2018512403A (ja) 2018-05-17
JP2018512403A5 JP2018512403A5 (enExample) 2019-04-18

Family

ID=55484986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017548211A Withdrawn JP2018512403A (ja) 2015-03-09 2016-03-07 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用

Country Status (18)

Country Link
US (1) US20180042929A1 (enExample)
EP (1) EP3268005A1 (enExample)
JP (1) JP2018512403A (enExample)
KR (1) KR20180013850A (enExample)
CN (1) CN107683138A (enExample)
AU (1) AU2016231260A1 (enExample)
BR (1) BR112017019190A2 (enExample)
CA (1) CA2978807A1 (enExample)
CL (1) CL2017002284A1 (enExample)
EA (1) EA201791975A1 (enExample)
HK (1) HK1250645A1 (enExample)
IL (1) IL254168A0 (enExample)
MA (1) MA43840A (enExample)
MX (1) MX2017011607A (enExample)
PH (1) PH12017501644A1 (enExample)
SG (1) SG11201707239WA (enExample)
TN (1) TN2017000385A1 (enExample)
WO (1) WO2016142313A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3068324A1 (en) * 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
CN111500587A (zh) * 2020-04-15 2020-08-07 湖南省科域生物医药科技有限公司 Pgr作为治疗子宫内膜异位症的产品中的用途及其检测pgr的试剂盒
EP4143569B1 (en) * 2020-05-01 2026-07-29 Mayo Foundation for Medical Education and Research Methods for treating endometrial cancer
WO2022140467A1 (en) * 2020-12-21 2022-06-30 Samson Pharma, Llc Topical compositions and methods of treating skin diseases and conditions with such compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2618489A1 (en) * 2005-09-07 2007-03-15 Laboratoires Serono S.A. Pi3k inhibitors for the treatment of endometriosis
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EA201201414A8 (ru) * 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014191938A1 (en) * 2013-05-31 2014-12-04 Novartis Ag Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer

Also Published As

Publication number Publication date
MA43840A (fr) 2018-11-21
SG11201707239WA (en) 2017-10-30
BR112017019190A2 (pt) 2018-04-24
MX2017011607A (es) 2018-04-10
CA2978807A1 (en) 2016-09-15
WO2016142313A1 (en) 2016-09-15
HK1250645A1 (zh) 2019-01-11
EA201791975A1 (ru) 2018-03-30
KR20180013850A (ko) 2018-02-07
TN2017000385A1 (en) 2019-01-16
PH12017501644A1 (en) 2018-03-12
US20180042929A1 (en) 2018-02-15
CL2017002284A1 (es) 2018-05-18
AU2016231260A1 (en) 2017-09-21
CN107683138A (zh) 2018-02-09
EP3268005A1 (en) 2018-01-17
IL254168A0 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
KR102304108B1 (ko) 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도
US10406162B2 (en) Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations
TWI639599B (zh) 經取代之２，３－二氫咪唑并［１，２－ｃ］喹唑啉之用途
CN107683138A (zh) 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途
CN102958540B (zh) 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合
US11185549B2 (en) Combination of a PI3K-inhibitor with an androgen receptor antagonist
TW201625261A (zh) ４－（４－氟－２－甲氧苯基）－ｎ－｛３－［（ｓ－甲磺醯亞胺醯基）甲基］苯基｝－１，３，５－三－２－胺於治療白血病之用途
HK1220121B (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
HK1194995A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HK1194995B (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190305

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20191003